{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Avotaciclib",
  "nciThesaurus": {
    "casRegistry": "1983983-41-0",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.",
    "fdaUniiCode": "Z6BYC0F36E",
    "identifier": "C163985",
    "preferredName": "Avotaciclib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C2185"
    ],
    "synonyms": [
      "AVOTACICLIB",
      "Avotaciclib",
      "BEY 1107",
      "BEY-1107",
      "BEY-A",
      "BEY1107",
      "BEY1107G",
      "BEY1107P",
      "CDK1 Inhibitor BEY1107"
    ]
  }
}